

A

- Abramson, S. N., McGonigle, P., and Molinoff, P. B. Evaluation of models for analysis of radioligand binding data, 103
- Aiyar, N., Nambi, P., Whitman, M., Stassen, F. L., and Crooke, S. T. Phorbol ester-mediated inhibition of vasopressin and β -adrenergic responses in a vascular smooth muscle cell line, 180
- Aiyar, N., *see* Stassen, F. L., 259, 267
- Albengres, E., Urien, S., Riant, P., Marcel, G. A., and Tillement, J.-P. Binding of two anthranilic acid derivatives to human albumin, erythrocytes, and lipoproteins: Evidence for glafenic acid high affinity binding, 294
- Amlaiky, N., Berger, J. G., Chang, W., McQuade, R. J., and Caron, M. G. Identification of the binding subunit of the D₁-dopamine receptor by photoaffinity crosslinking, 129
- Anders, M. W., *see* Elfarra, A. A., 208
- Andres, H. H., Vogel, R. S., Tarr, G. E., Johnson, L., and Weber, W. W. Purification, physicochemical, and kinetic properties of liver acetyl-CoA:arylamine N-acetyltransferase from rapid acetylator rabbits, 446
- Ansell, J., *see* Norman, J. A., 535
- Audigier, Y., *see* Homburger, V., 313
- Ayisi, N. K., Wall, R. A., Wanklin, R. J., Machida, H., De Clercq, E., and Sacks, S. L. Comparative metabolism of E-5-(2-bromovinyl)-2'-deoxyuridine and 1- β -D-arabinofuranosyl-3-5-(2-bromovinyl)uracil in herpes simplex virus-infected cells, 422

B

- Baden, D. G., *see* Sharkey, R. G., 273
- Baker, W. M., *see* Berman, H. A., 610
- Balgavý, P., *see* Ondriaš, K., 97
- Balwierczak, J. L., Johnson, C. L., and Schwartz, A. The relationship between the binding site of [³H]-d-cis-diltiazem and that of other non-dihydropyridine calcium entry blockers in cardiac sarcolemma, 175
- Barber, K. R., *see* Juliano, R. L., 1
- Barrett, R. W., *see* Goldstein, A., 603
- Battaglia, G., *see* Hess, E. J., 50
- Belenky, G. L., *see* Hitzemann, R. J., 562
- Bend, J. R., *see* Coughtrie, M. W. H., 585
- Berger, J. G., *see* Amlaiky, N., 129
- Berlan, M., *see* Taouis, M., 89
- Berman, H. A., Decker, M. M., Nowak, M. W., Leonard, K. J., McCauley, M., Baker, W. M., and Taylor, P. Site selectivity of fluorescent bisquaternary phenanthridium ligands for acetylcholinesterase, 610
- Bertolasi, V., *see* Borea, P. A., 334
- Bielkiewicz-Vollrath, B., Carpenter, J. R., Shulz, R., and Cook, D. A. Early production of 1,4,5-inositol trisphosphate and 1,3,4,5-inositol tetrakisphosphate by histamine and carbachol in ileal smooth muscle, 513
- Blanchard, S. G., Lee, P. H. K., Pugh, W. W., Hong, J. S., and Chang, K.-J. Characterization of the binding of a morphine (μ) receptor-specific ligand: Tyr-Pro-NMePhe-D-Pro-NH₂ [³H]-PL17, 326
- Blatt, S., *see* Hitzemann, R. J., 562
- Bockaert, J., *see* Homburger, V., 313
- Bohmker, K., *see* Meller, E., 592
- Borchardt, R. T., *see* Keller, B. T., 485
- Borea, P. A., Gilli, G., Bertolasi, V., and Ferretti, V. Stereochemical features controlling binding and intrinsic activity properties of benzodiazepine-receptor ligands, 334
- Brabet, P., *see* Homburger, V., 313
- Brown, A. M., *see* Hamilton, S. L., 221

- Brown, A. M., *see* Kunze, D. L., 401
- Brush, K., *see* Hamilton, S. L., 221
- Buller, A. L., Clapper, M. L., and Tew, K. D. Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines, 575
- Burchell, B., *see* Coughtrie, M. W. H., 585
- Burgevin, M. C., *see* Doble, A., 42
- Burke, T. G., Morin, M. J., Sartorelli, A. C., Lane, P. E., and Tritton, T. R. Function of the anthracycline amino group in cellular transport and cytotoxicity, 552
- Butt, T. R., *see* Monia, B. P., 21

C

- Caron, M. G., *see* Amlaiky, N., 129
- Carpenter, J. R., *see* Bielkiewicz-Vollrath, B., 513
- Carver, G. T., *see* Vanderslice, R. R., 320
- Casida, J. E., *see* Pessah, I. N., 232
- Catterall, W. A., *see* Sharkey, R. G., 273
- Chang, K.-J., *see* Blanchard, S. G., 326
- Chang, W., *see* Amlaiky, N., 129
- Chapekar, M. S., Hartman, K. D., Knode, M. C., and Glazer, R. I. Synergistic effect of retinoic acid and calcium ionophore A23187 on differentiation, *c-myc* expression, and membrane tyrosine kinase activity in human promyelocytic leukemia cell line HL-60, 140
- Chen, G.-X., Mueller, C., Wendlinger, M., and Zolg, J. W. Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite *Plasmodium falciparum*, 430
- Cheng, H.-Y., *see* Wong, A., 368
- Cheng, Y.-C., *see* Parker, W. B., 146
- Chiaroni, A., *see* Dodd, R. H., 74
- Churchill, P. F., Churchill, S. A., Martin, M. V., and Guengerich, F. P. Characterization of a rat liver cytochrome P-450_{UT-H} cDNA clone and comparison of mRNA levels with catalytic activity, 152
- Churchill, S. A., *see* Churchill, P. F., 152
- Clapper, M. L., *see* Buller, A. L., 575
- Clarke, L., Rosowsky, A., and Waxman, D. J. Inhibition of human liver folylpolyglutamate synthetase by non- γ -glutamylatable antifolate analogs, 122
- Contreras-Rodríguez, J. L., *see* García-Sáinz, J. A., 253
- Cook, D. A., *see* Bielkiewicz-Vollrath, B., 513
- Costa, T., *see* Vachon, L., 159
- Coughtrie, M. W. H., Burchell, B., Sheperd, I. M., and Bend, J. R. Defective induction of phenol glucuronidation by 3-methylcholanthrene in Gunn rats is due to the absence of a specific UDP-glucuronosyltransferase isoenzyme, 585
- Couraud, F., *see* Sharkey, R. G., 273
- Creese, I., *see* Hess, E. J., 50
- Crooke, S. T., *see* Aiyar, N., 180
- Crooke, S. T., *see* Mong, S., 35
- Crooke, S. T., *see* Monia, B. P., 21
- Crooke, S. T., *see* Nakada, M. T., 377
- Crooke, S. T., *see* Stassen, F. L., 259, 267
- Crooke, S. T., *see* Wong, A., 368

D

- Dannan, G. A., *see* Murray, M., 117
- Davis, K. H., *see* Lyon, R. A., 194
- Decker, M. M., *see* Berman, H. A., 610
- De Clercq, E., *see* Ayisi, N. K., 422
- De Clercq, E., *see* Yokota, T., 493
- de la Garza, M. C., *see* García-Sáinz, J. A., 253

- de Montellano, P. R. O., and Watanabe, M. D. Free radical pathways in the *in vitro* hepatic metabolism of phenelzine, 213
- Devaux, G., *see* Dodd, R. H., 74
- Doble, A., Ferris, O., Burgevin, M. C., Menager, J., Uzan, A., Dubroeuq, M. C., Renault, C., Gueremy, C., and Le Fur, G. Photoaffinity labeling of peripheral-type benzodiazepine-binding sites, 42
- Dodd, R. H., Ouannès, C., Chiaroni, A., Riche, C., Poissonett, G., Rossier, J., Devaux, G., and Potier, P. Molecular structure of 3-(methoxycarbonyl) amino- β -carboline, a selective antagonist of the sedative effects of diazepam, 74
- Doi, M., *see* Ishida, T., 410
- Domin, B. A., *see* Vanderslice, R. R., 320
- Dubroeuq, M. C., *see* Doble, A., 42
- Dyson, J., *see* Patel, T. B., 638

E

- Ecker, D. J., *see* Monia, B. P., 21
- Elfarra, A. A., Lash, L. H., and Anders, M. W. α -Ketoacids stimulate rat renal cysteine conjugate β -lyase activity and potentiate the cytotoxicity of S-(1,2-dichlorovinyl)-L-cysteine, 208
- Ettouati, W. S., and Jacobs, R. S. Effect of pseudopterosin A on cell division, cell cycle progression, DNA, and protein synthesis in cultured sea urchin embryos, 500

F

- Farrell, G. C., *see* Murray, M., 117
- Fernandes, K. G., *see* Lippiello, P. M., 392
- Ferretti, V., *see* Borea, P. A., 334
- Ferris, O., *see* Doble, A., 42
- Fleming, J. T., *see* Lewis, J. A., 185
- Fortman, C. S., *see* Johlin, F. C., 557
- Franklin, M. R., *see* Ritter, J. K., 135
- Frenkel, G. D., Walcott, A., and Middleton, C. Inhibition of RNA and DNA polymerases by the product of the reaction of selenite with sulfhydryl compounds, 112
- Friedhoff, A. J., *see* Meller, E., 592

G

- García-Sáinz, J. A., de la Garza, M. C., Contreras-Rodríguez, J. L., and Nájera-Alvarado, A. Effects of histamine on the metabolism of isolated rat hepatocytes: Roles of H₁- and H₂-histamine receptors, 253
- Geertsen, S., *see* Quik, M., 385
- Gerhards, J., *see* Mehler, E. L., 284
- Gerst, J. E., Sole, J., and Salomon, Y. Dual regulation of β -MSH receptor function and adenylate cyclase by calcium and guanosine nucleotides in the M2R melanoma cell line, 81
- Giachelli, C. M., and Omiecinski, C. J. Developmental regulation of cytochrome P-450 genes in the rat, 477
- Gilli, G., *see* Borea, P. A., 334
- Glazer, R. I., *see* Chapekar, M. S., 140
- Goldstein, A., and Barrett, R. W. Ligand dissociation constants from competition binding assays: Errors associated with ligand depletion, 603
- Goldstein, A., *see* Mosberg, H. I., 599
- Goldstein, M., *see* Meller, E., 592
- Grant, C. W. M., *see* Juliano, R. L., 1
- Green, J. P., *see* Shenker, A., 357
- Gresh, N. Theoretical studies of the binding of trifluoperazine derivatives to site (82-93) of calmodulin: Effect of lengthenings of the methylene linker chain on the binding affinity, 617
- Guengerich, F. P., *see* Churchill, P. F., 152
- Guengerich, F. P., *see* Murray, M., 117
- Gueremy, C., *see* Doble, A., 42
- Gutmann, H. R., *see* Smith, B. A., 438

H

- Hagiwara, M., Inagaki, M., and Hidaka, H. Specific binding of a novel compound, N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H-8) to the active site of cAMP-dependent protein kinase, 523
- Hamilton, S. L., *see* Kunze, D. L., 401
- Hamilton, S. L., Yatani, A., Brush, K., Schwartz, A., and Brown, A. M. A comparison between the binding and electrophysiological effects of dihydropyridines on cardiac membranes, 221
- Hartman, K. D., *see* Chapekar, M. S., 140
- Harvison, P. J., *see* Porubek, D. J., 647
- Hawkes, M. J., *see* Kunze, D. L., 401
- Heckman, G., *see* Stassen, F. L., 259, 267
- Herz, A., *see* Vachon, L., 159
- Hess, E. J., Battaglia, G., Norman, A. B., Creese, I. Differential modification of striatal D₁ dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline *in vivo* and *in vitro*, 50
- Hidaka, H., *see* Hagiwara, M., 523
- Hitzemann, B. A., *see* Hitzemann, R. J., 562
- Hitzemann, R. J., Hitzemann, B. A., Blatt, S., Meyerhoff, J. L., Tortella, F. C., Kenner, J. R., Belenky, G. L., and Holaday, J. W. Repeated electroconvulsive shock: Effect on sodium dependency and regional distribution of opioid-binding sites, 562
- Hoffman, K., *see* Mong, S., 35
- Holaday, J. W., *see* Hitzemann, R. J., 562
- Homburger, V., Brabet, P., Audigier, Y., Pantaloni, C., Bockaert, J., and Rouot, B. Immunological localization of the GTP-binding protein G_o in different tissues of vertebrates and invertebrates, 313
- Hong, J. S., *see* Blanchard, S. G., 326
- Hosokawa, M., Maki, T., and Satoh, T. Multiplicity and regulation of hepatic microsomal carboxylesterase in rats, 579
- Hughes, R. J., *see* Terman, B. I., 12
- Hunter, D. D., *see* Selfe, S., 529
- Hwang, S. M., *see* Wong, A., 368

I

- Ijzerman, A., *see* Severne, Y., 69
- In, Y., *see* Ishida, T., 410
- Inagaki, M., *see* Hagiwara, M., 523
- Inoue, M., *see* Ishida, T., 410
- Insel, P. A., *see* Terman, B. I., 12
- Irshaid, Y. M., and Tephly, T. R. Isolation and purification of two human liver UDP-glucuronosyltransferases, 27
- Ishida, T., In, Y., Shibata, M., Doi, M., Inoue, M., and Yanagisawa, I. On the structure-activity relationship of histamine H₂-receptor antagonists based on the x-ray crystal structures and ¹H-NMR spectra of amidine derivatives, 401

J

- Jacobs, R. S., *see* Ettouati, W. S., 500
- Jančinová, V., *see* Ondriaš, K., 97
- Johlin, F. C., Fortman, C. S., Ngheim, D. D., and Tephly, T. R. Studies on the role of folic acid and folate-dependent enzymes in human methanol poisoning, 557
- Johnson, C. L., *see* Balwierczak, J. L., 175
- Johnson, J. A., *see* Wallace, K. B., 307
- Johnson, L., *see* Andres, H. H., 446
- Johnson, R. A., *see* Martinson, E. A., 247
- Johnson, R. D., and Minneman, K. P. Differentiation of α_1 -adrenergic receptors linked to phosphatidylinositol turnover and cyclic AMP accumulation in rat brain, 239
- Joost, H. G., and Steinfelder, H. J. Forskolin inhibits insulin-stimulated glucose transport in rat adipose cells by a direct interaction with the glucose transporter, 279
- Jover, E., *see* Sharkey, R. G., 273

- Juliano, R. L., Grant, C. W. M., Barber, K. R., and Kalp, M. A. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes, 1
- K**
- Kalp, M. A., *see* Juliano, R. L., 1
 Kamaya, H., *see* Tsai, Y.-S., 623
 Kellar, K. J., *see* Martino-Barrows, A. M., 169
 Keller, B. T., and Borchardt, R. T. Adenosine dialdehyde: A potent inhibitor of vaccinia virus multiplication in mouse L929 cells, 485
 Kenner, J. R., *see* Hitzemann, R. J., 562
 Klopman, G., and Macina, O. T. Computer-automated structure evaluation of antileukemic 9-anilinoacridines, 457
 Knaus, E. E., *see* Suzuki, S., 301
 Knode, M. C., *see* Chapekar, M. S., 140
 Konno, K., *see* Yokota, T., 493
 Kunze, D. L., Hamilton, S. L., Hawkes, M. J., and Brown, A. M. Dihydropyridine binding and calcium channel function in clonal rat adrenal medullary tumor cells, 401
- L**
- Lafontan, M., *see* Taouis, M., 89
 Landvatter, S., *see* Stassen, F. L., 267
 Lane, P. E., *see* Burke, T. G., 552
 Lash, L. H., *see* Elfarra, A. A., 208
 Lee, P. H. K., *see* Blanchard, S. G., 326
 Le Fur, G., *see* Doble, A., 42
 Leonard, K. J., *see* Berman, H. A., 610
 Lewis, J. A., Fleming, J. T., McLafferty, S., Murphy, H., and Wu, C. The levamisole receptor, a cholinergic receptor of the nematode *Caenorhabditiselegans*, 185
 Lippiello, P. M., Sears, S. B., and Fernandes, K. G. Kinetics and mechanism of L-[³H]nicotine binding to putative high affinity receptor sites in rat brain, 392
 Lyon, R. A., Davis, K. H., and Titeler, M. ³H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT₂ receptors, 194
- M**
- Ma, S.-M., *see* Tsai, Y.-S., 623
 Maayani, S., *see* Shenker, A., 357
 Machida, H., *see* Ayisi, N. K., 422
 Macina, O. T., *see* Klopman, G., 457
 Maki, T., *see* Hosokawa, M., 579
 Marcel, G. A., *see* Albengres, E., 294
 Martin, M. V., *see* Churchill, P. F., 152
 Martino-Barrows, A. M., and Kellar, K. J. [³H]Acetylcholine and [³H](-)nicotine label the same recognition site in rat brain, 169
 Martinson, E. A., Johnson, R. A., and Wells, J. N. Potent adenosine receptor antagonists that are selective for the A₁ receptor subtype, 247
 Mason, R. P., *see* Mottley, C., 417
 Mazurek, A. P., Osman, R., and Weinstein, H. Molecular determinants for recognition of triazole and tetrazole analogs of histamine H₂-receptors, 345
 McCauley, M., *see* Berman, H. A., 610
 McGonigle, P., *see* Abramson, S. N., 103
 McLafferty, S., *see* Lewis, J. A., 185
 McQuade, R. J., *see* Amlaiky, N., 129
 Mehler, E. L., and Gerhards, J. Electronic determinants of the anti-inflammatory action of benzoic and salicylic acids, 284
 Mela-Riker, L., *see* Vlessis, A. A., 643
 Meller, E., Bohmaker, K., Namba, Y., Friedhoff, A. J., and Goldstein, M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors, 592
 Menager, J., *see* Doble, A., 42
 Meyerhoff, J. L., *see* Hitzemann, R. J., 562
 Middleton, C., *see* Frenkel, G. D., 112
 Minneman, K. P., *see* Johnson, R. D., 239
 Mirabelli, C. K., *see* Monia, B. P., 21
 Misra, H. K., *see* Suzuki, S., 301
 Moldéus, P., *see* Porubek, D. J., 647
 Molinoff, P. B., *see* Abramson, S. N., 103
 Mong, S., Hoffman, K., Wu, H.-L., and Crooke, S. T. Leukotriene-induced hydrolysis of inositol lipids in guinea pig lung: Mechanism of signal transduction for leukotriene-D₄ receptors, 35
 Monia, B. P., Butt, T. R., Mirabelli, C. K., Ecker, D. J., Sternberg, E., and Crooke, S. T. Induction of metallothionein is correlated with resistance to auranofin, a gold compound, in Chinese hamster ovary cells, 21
 Morin, M. J., *see* Burke, T. G., 552
 Mosberg, H. I., Omnaas, J. R., and Goldstein, A. Structural requirements for δ opioid receptor binding, 599
 Mottley, C., Toy, K., and Mason, R. P. Oxidation of thiol drugs and biochemicals by the lactoperoxidase/hydrogen peroxide system, 417
 Mueller, C., *see* Chen, G.-X., 430
 Murphy, H., *see* Lewis, J. A., 185
 Murray, M., Zaluzny, L., Dannan, G. A., Guengerich, F. P., and Farrell, G. C. Altered regulation of cytochrome P-450 enzymes in choline-deficient cirrhotic male rat liver: Impaired regulation and activity of the male-specific androst-4-ene-3,17-dione 16 α -hydroxylase, cytochrome P-450_{UT-A}, in hepatic cirrhosis, 117
- N**
- Nájera-Alvarado, A., *see* García-Sáinz, J. A., 253
 Nakada, M. T., Stadel, J. M., Poksay, K. S., and Crooke, S. T. Glucocorticoid regulation of β -adrenergic receptors in 3T3-L1 preadipocytes, 377
 Namba, Y., *see* Meller, E., 592
 Nambi, P., *see* Aiyar, N., 180
 Nambi, P., *see* Stassen, F. L., 259, 267
 Nathanson, N. M., *see* Selfe, S., 529
 Nelson, S. D., *see* Porubek, D. J., 647
 Nerme, V., *see* Severne, Y., 69
 Ngeim, D. D., *see* Johlin, F. C., 557
 Norman, A. B., *see* Hess, E. J., 50
 Norman, J. A., Ansell, J., Stone, G. A., Wennogle, L. P., and Wasley, J. W. F. CGS 9343B, a novel, potent, and selective inhibitor of calmodulin activity, 535
 Nowak, M. W., *see* Berman, H. A., 610
- O**
- Omicinski, C. J., *see* Giachelli, C. M., 477
 Omnaas, J. R., *see* Mosberg, H. I., 599
 Ondrias, K., Staško, A., Jancinová, V., and Balgavý, P. Comparison of the effect of eleven β -adrenoceptor blocking drugs in perturbing lipid membrane: An ESR spectroscopy study, 97
 Osman, R., *see* Mazurek, A. P., 345
 Ouannès, C., *see* Dodd, R. H., 74
- P**
- Pantaloni, C., *see* Homburger, V., 313
 Parker, W. B., and Cheng, Y.-C. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs, 146
 Patel, T. B., Rashed, H. M., Dyson, J., and Waller, F. M. Stimulation of biliary glutathione secretion by sulfonyleureas, 638
 Pessah, I. N., Stambuk, R. A., and Casida, J. E. Ca²⁺-Activated ryandine binding: Mechanisms of sensitivity and intensity modulation by Mg²⁺, caffeine, and adenine nucleotides, 232
 Philpot, R. M., *see* Tynes, R. E., 569
 Philpot, R. M., *see* Vanderslice, R. R., 320

- Poissonett, G., *see* Dodd, R. H., 74
 Poksay, K. S., *see* Nakada, M. T., 377
 Porubek, D. J., Rundgren, M., Harvison, P. J., Nelson, S. D., and Moldéus, P. Investigation of mechanisms of acetaminophen toxicity in isolated rat hepatocytes with the acetaminophen analogues 3,5-dimethylacetaminophen and 2,6-dimethylacetaminophen, 647
 Potier, P., *see* Dodd, R. H., 74
 Pugh, W. W., *see* Blanchard, S. G., 326
- Q**
- Quik, M., Geertsen, S., and Trifaró, J. M. Marked up-regulation of the α -bungarotoxin site in adrenal chromaffin cells by specific nicotinic antagonists, 385
- R**
- Rashed, H. M., *see* Patel, T. B., 638
 Reinke, L. A., Tupper, J. S., Smith, P. R., and Sweeny, D. J. Diminished pentose cycle flux in perfused livers of ethanol-fed rats, 631
 Renault, C., *see* Doble, A., 42
 Riant, P., *see* Albengres, E., 294
 Riche, C., *see* Dodd, R. H., 74
 Ringdahl, B. Selectivity of partial agonists related to oxotremorine based on differences in muscarinic receptor reserve between the guinea pig ileum and urinary bladder, 351
 Ritter, J. K., and Franklin, M. R. Clotrimazole induction of cytochrome P-450: Dose-differentiated isozyme induction, 135
 Rosowsky, A., *see* Clarke, L., 122
 Rossier, J., *see* Dodd, R. H., 74
 Rouot, B., *see* Homburger, V., 313
 Rundgren, M., *see* Porubek, D. J., 647
- S**
- Sacks, S. L., *see* Ayisi, N. K., 422
 Salomon, Y., *see* Gerst, J. E., 81
 Sartorelli, A. C., *see* Burke, T. G., 552
 Satoh, T., *see* Hosokawa, M., 579
 Schaeffer, V. H., and Stevens, J. L. The transport of S-cysteine conjugates in LLC-PK₁ cells and its role in toxicity, 506
 Schmidt, D., *see* Stassen, F. L., 259, 267
 Schwartz, A., *see* Balwierczak, J. L., 175
 Schwartz, A., *see* Hamilton, S. L., 221
 Sears, S. B., *see* Lippiello, P. M., 392
 Selfe, S., Hunter, D. D., Shattuck, R. L., Nathanson, N. M., and Storm, D. R. Alteration of intracellular cAMP levels and beating rates of cultured chick cardiac cells by *Bordetella pertussis* adenylate cyclase, 529
 Severne, Y., Ijzerman, A., Nerme, V., Timmerman, H., and Vauquelin, G. Shallow agonist competition binding curves for β -adrenergic receptors: The role of tight agonist binding, 69
 Sharkey, R. G., Jover, E., Couraud, F., Baden, D. G., and Catterall, W. A. Allosteric modulation of neurotoxin binding to voltage-sensitive sodium channels by *Ptychodiscus brevis* Toxin 2, 273
 Shattuck, R. L., *see* Selfe, S., 529
 Shenker, A., Maayani, S., Weinstein, H., and Green, J. P. Pharmacological characterization of two 5-hydroxytryptamine receptors coupled to adenylate cyclase in guinea pig hippocampal membranes, 357
 Sheperd, I. M., *see* Coughtrie, M. W. H., 585
 Shibata, M., *see* Ishida, T., 410
 Shigeta, S., *see* Yokota, T., 493
 Shulz, R., *see* Bielkiewicz-Vollrath, B., 513
 Slivka, S. R., *see* Terman, B. I., 12
 Smith, B. A., Springfield, J. R., and Gutmann, H. R. Solvolysis and metabolic degradation, by rat liver, of the ultimate carcinogen, N-sulfonyl-2-acetylaminofluorene, 438
 Smith, P. R., *see* Reinke, L. A., 631
 Sole, J., *see* Gerst, J. E., 81
 Springfield, J. R., *see* Smith, B. A., 438
 Stadel, J. M., *see* Nakada, M. T., 377
 Stambuk, R. A., *see* Pessah, I. N., 232
 Staško, A., *see* Ondrias, K., 97
 Stassen, F. L., Heckman, G., Schmidt, D., Aiyar, N., Nambi, P., and Crooke, S. T. Identification and characterization of vascular (V₁) vasopressin receptors of an established smooth muscle cell line, 259
 Stassen, F. L., Heckman, G., Schmidt, D., Nambi, P., Aiyar, N., Landvatter, S., and Crooke, S. T. A novel radiolabeled vasopressin antagonist: [³H-Phe]-des-Glyd(CH₂)₆D-Tyr(Et)VAVP, [³H]-SK&F 101926, 267
 Stassen, F. L., *see* Aiyar, N., 180
 Steinfelder, H. J., *see* Joost, H. G., 279
 Sternberg, E., *see* Monia, B. P., 21
 Stevens, J. L., *see* Schaeffer, V. H., 506
 Stone, G. A., *see* Norman, J. A., 535
 Storm, D. R., *see* Selfe, S., 529
 Sutherland, R. L., *see* Watts, C. K. W., 541
 Suzuki, S., Misra, H. K., Wiebe, L. I., Knaus, E. E., and Tyrrell, D. L. J. A proposed mechanism for the selective inhibition of human cytomegalovirus replication by 1-(2'-Deoxy-2'-fluoro- β -D-arabinofuranosyl)-5-fluorouracil, 301
 Sweeny, D. J., *see* Reinke, L. A., 631
- T**
- Taouis, M., Berlan, M., and Lafontan, M. α_2 -Adrenergic receptor turnover in adipose tissue and kidney: Irreversible blockade of α_2 -adrenergic receptors by benextramine, 89
 Tarr, G. E., *see* Andres, H. H., 446
 Taylor, P., *see* Berman, H. A., 610
 Tephly, T. R., *see* Irshaid, Y. M., 27
 Tephly, T. R., *see* Johlin, F. C., 557
 Terman, B. I., Slivka, S. R., Hughes, R. J., and Insel, P. A. α_1 -Adrenergic receptor-linked guanine nucleotide-binding protein in muscle and kidney epithelial cells, 12
 Tew, K. D., *see* Buller, A. L., 575
 Tillement, J.-P., *see* Albengres, E., 294
 Timmerman, H., *see* Severne, Y., 69
 Titeler, M., *see* Lyon, R. A., 194
 Toews, M. L. Comparison of agonist-induced changes in β - and α_1 -adrenergic receptors of DDT₁MF-2 cells, 58
 Tortella, F. C., *see* Hitzemann, R. J., 562
 Toy, K., *see* Mottley, C., 417
 Trifaró, J. M., *see* Quik, M., 385
 Tritton, T. R., *see* Burke, T. G., 552
 Tsai, Y.-S., Ma, S.-M., Kamaya, H., and Ueda, I. Fourier transform infrared studies on phospholipid hydration: Phosphate-oriented hydrogen bonding and its attenuation by volatile anesthetics, 623
 Tupper, J. S., *see* Reinke, L. A., 631
 Tyne, R. E., and Philpot, R. M. Tissue- and species-dependent expression of multiple forms of mammalian microsomal flavin-containing monooxygenase, 569
 Tyrrell, D. L. J., *see* Suzuki, S., 301
- U**
- Ueda, I., *see* Tsai, Y.-S., 623
 Urien, S., *see* Albengres, E., 294
 Uzan, A., *see* Doble, A., 42
- V**
- Vachon, L., Costa, T., and Herz, A. GTPase and adenylate cyclase desensitize at different rates in NG108-15 cells, 159
 Vanderslice, R. R., Domin, B. A., Carver, G. T., and Philpot, R. M. Species-dependent expression and induction of homologues of rabbit cytochrome P-450 isozyme 5 in liver and lung, 320
 Vauquelin, G., *see* Severne, Y., 69

- Verbruggen, A., *see* Yokota, T., 493
 Vlessis, A. A., and Mela-Riker, L. Selenite-induced NAD(P)H oxidation and calcium release in isolated mitochondria: Relationship to *in vivo* toxicity, 643
 Vogel, R. S., *see* Andres, H. H., 446
- W**
- Waddell, K. S., *see* Williams, M. V., 200
 Walcott, A., *see* Frenkel, G. D., 112
 Wall, R. A., *see* Ayisi, N. K., 422
 Wallace, K. B., and Johnson, J. A. Oxygen-dependent effect of microsomes on the binding of doxorubicin to rat hepatic nuclear DNA, 307
 Waller, F. M., *see* Patel, T. B., 638
 Wanklin, R. J., *see* Ayisi, N. K., 422
 Wasley, J. W. F., *see* Norman, J. A., 535
 Watanabe, M. D., *see* de Montellano, P. R. O., 208
 Watts, C. K. W., and Sutherland, R. L. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites, 541
 Waxman, D. J., *see* Clarke, L., 122
 Weber, W. W., *see* Andres, H. H., 446
 Weinstein, H., *see* Mazurek, A. P., 345
 Weinstein, H., *see* Shenker, A., 357
 Wells, J. N., *see* Martinson, E. A., 247
 Wendlinger, M., *see* Chen, G.-X., 430
- Wennogle, L. P., *see* Norman, J. A., 535
 Whitman, M., *see* Aiyar, N., 180
 Wiebe, L. I., *see* Suzuki, S., 301
 Williams, M. V., Winters, T., and Waddell, K. S. *In vivo* effects of mercury (II) on dUTPase, DNA polymerase (α, β), and uracil-DNA glycosylase activities in cultured human cells: Relationship to DNA damage, DNA repair, and cytotoxicity, 200
 Winters, T., *see* Williams, M. V., 200
 Wong, A., Hwang, S. M., Cheng, H.-Y., and Crooke, S. T. Structure-activity relationships of β -adrenergic receptor-coupled adenylate cyclase: Implications of a redox mechanism for the action of agonists at β -adrenergic receptors, 368
 Wu, C., *see* Lewis, J. A., 185
 Wu, H.-L., *see* Mong, S., 35
- Y**
- Yanagisawa, I., *see* Ishida, T., 410
 Yatani, A., *see* Hamilton, S. L., 221
 Yokota, T., Konno, K., Shigeta, S., Verbruggen, A., and De Clercq, E. Incorporation of (*E*)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of Varicella-Zoster virus (TK⁺ and TK⁻ strains)-infected cells, 493
- Z**
- Zaluzny, L., *see* Murray, M., 117
 Zolg, J. W., *see* Chen, G.-X., 430

A

- A23187, retinoic acid and, differentiation, HL-60 cells, 140
 Acetaminophen, mechanisms of toxicity, hepatocytes, acetaminophen analogues (rat), 647
 Acetylcholine, nicotine and, same recognition site, brain (rat), 169
 Acetylcholinesterase, site selectivity, fluorescent bisquaternary phenanthridinium ligands, 610
 Acetyl-CoA:arylamine *N*-acetyltransferase, liver, rapid acetylator rabbits, 446
N-Acetylcysteine, oxidation of thiol drugs, lactoperoxidase/hydrogen peroxide system, 417
N-Acetyltransferase, liver, rapid acetylator rabbits, 446
 Adenine nucleotides, ryanodine binding, calcium-activated, mechanisms of modulation (rabbit), 232
 Adenosine dialdehyde, vaccinia virus multiplication, L929 cells (mouse), 485
 Adenosine monophosphate, cyclic
 accumulation in brain, phosphatidylinositol turnover, α_1 -Adrenergic receptors (rat), 239
 phorbol ester-mediated inhibition, vasopressin, β -adrenergic responses (rat), 180
 Adenosine triphosphate, cAMP-dependent protein kinase, specific binding, *N*-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide, 523
 Adenylate cyclase
 Bordetella pertussis, cardiac cells' beating rate, cAMP levels (chick), 529
 coupled with β -adrenergic receptors, action of agonists, redox mechanism (frog), 368
 D₁ dopamine receptor, modification, *N*-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (rat), 50
 guanosine triphosphatase and, desensitization, NG108-15 cells, 159
 β -melanotropin receptor function, calcium and guanosine nucleotides, M2R melanoma cell line, 81
 radioligand binding, evaluation of models, analysis, 103
 serotonin receptors, characterization, hippocampal membranes (guinea pigs), 357
 Adipocytes, α_2 -adrenergic turnover, irreversible blockade, benextramine (hamster), 89
 Adipose cells, glucose transport activity, forskolin inhibition (rat), 279
 ADP-ribosylate, GTP-binding protein, immunological localization, vertebrates and invertebrates, 313
 Adrenal medulla
 α -bungarotoxin site, up-regulation, nicotinic antagonists, 385
 tumor cells, dihydropyridine binding, calcium channel function (rat), 401
 Adrenoceptors
 α , guanine nucleotide-binding protein, muscle and kidney epithelial cells, 12
 α -1, phosphatidylinositol turnover, cyclic AMP accumulation in brain (rat), 239
 α -2, turnover, adipose tissue and kidney (hamster), 89
 α and β , agonist-induced changes, DDT₁ MF-2 cells, 58
 β
 blocking drugs, perturbation of lipid membrane, 97
 coupled to adenylate cyclase, redox mechanism (frog), 368
 glucocorticoid regulation, 3T3-L1 preadipocytes, 377
 shallow agonist competition, tight agonist binding, 69
 Aging, selenite-induced NADPH oxidation, calcium release (guinea pig), 643
 Agonists, shallow, competition binding, β adrenoceptors, 69
 Albumin, blood binding, anthranilic acid derivatives, 294
 Amidine compounds, histamine H₂-receptor antagonists, structure-activity relationship, 410
 2-Aminofluorene, cytochrome P-450 isozyme 5, species-dependent expression, liver and lung (rabbit, guinea pig, mouse, monkey, hamster, rat), 320
 Amphotericin B, incorporation into liposomes, selective toxicity, mechanism, 1
 Anesthetics, volatile, Fourier transform infrared studies, phospholipid hydration, 623
 9-Anilinoacridines, antileukemic, computer-automated structure evaluation, 457
 Antagonists
 adenosine receptor, selectivity, A₁ receptor subtype, 247
 vasopressin, SK&F 101926, 267
 Anthracycline, function of amino group, cellular transport, cytotoxicity, 552
 Antiestrogens, microsomal binding sites, ligand specificity, 541
 Antifolate analogs, non- γ -glutamylatable, inhibition, foplypolyglutamate synthetase, 122
 Antiinflammatory drugs, non-steroidal, electronic determinants, benzoic and salicylic acid (mouse), 284
 Arabinofuranosyl analogs, inhibition, DNA primase, 146
 1- β -D-Arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, *E*-5-(2-bromovinyl)-2'-deoxyuridine and, comparative metabolism, herpes simplex virus-infected cells, 422
 1- β -D-Arabinofuranosylthymine, compared to 1-(2'-deoxy-2'-fluoro- β -D-arabinofuranosyl)-5-fluorouracil, selective inhibition, human cytomegalovirus replication, 301
 Arginine vasopressin, *see* Vasopressin
 Assays
 competition binding, ligand dissociation constants, 603
 radioligand binding, model evaluation, analysis, 103
 Auranofin, resistance, induction of metallothionein, Chinese hamster ovary cells, 21

B

- BAB drugs, perturbation of lipid membrane, ESR spectroscopy, 97
 Benextramine, irreversible blockade, α_2 -adrenergic receptor turnover (hamster), 89
 Benzodiazepine
 binding sites, peripheral-type, photoaffinity labeling (rat), 42
 receptor ligands, stereochemical features, 334
 Benzoic acid, anti-inflammatory action, electronic determinants (mouse), 284
 Bepridil, diltiazem, binding site, cardiac sarcolemma (dog), 175
 Bile, glutathione secretion, stimulation of, sulfonyleureas (rat), 638
Bordetella pertussis, adenylate cyclase, intracellular cAMP levels, cardiac cells' rate of beating (chick), 529
 Brain
 characterization of binding, P17 (rat), 326
 GTP-binding protein, immunological localization, vertebrates and invertebrates, 313
 high affinity receptor sites, nicotine binding, kinetics and mechanism (rat), 392
 recognition site, acetylcholine, nicotine (rat), 169
 repeated electroconvulsive shock, effect, opioid-binding sites, 562
 Breast cancer cells, ligand specificity, microsomal antiestrogen-binding sites, 541
 4-Bromo-2,5-dimethoxyphenylisopropylamine, labeling, serotonin receptors, 194
E-5-(2-Bromovinyl)-2'-deoxyuridine, 1- β -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil and, comparative metabolism, herpes simplex virus-infected cells, 422

- Bufuralol, cytochrome P-450 cDNA clone, characterization, compared with mRNA levels (rat), 152
- α -Bungarotoxin
levamisole receptor, *Caenorhabditis elegans*, 185
up-regulation of site, adrenal chromaffin cells, nicotinic antagonists, 385
- C**
- Caenorhabditis elegans*, levamisole receptor, 185
- Caffeine, ryanodine binding, calcium-activated, mechanisms of modulation (rabbit), 232
- Calcium
entry blockers, diltiazem, cardiac sarcolemma (dog), 175
guanosine nucleotides and, β -melanotropin receptor function, M2R melanoma cell line, 81
phosphatidylinositol turnover, cyclic AMP accumulation in brain, α_1 -adrenergic receptors (rat), 239
release in isolated mitochondria, NADPH oxidation, selenite-induced (guinea pig), 643
- Calcium channels
binding and electrophysiological effects, dihydropyridines, cardiac membranes (guinea pig), 221
dihydropyridine binding and, adrenal medullary tumor cells (rat), 401
ryanodine binding, mechanisms of modulation (rabbit), 232
- Calmodulin
binding site (82-93), trifluoperazine derivatives, 617
inhibitor, CGS 9343B, 535
- Captopril, oxidation of thiol drugs, lactoperoxidase/hydrogen peroxide system, 417
- Carbachol
 α -bungarotoxin site, up-regulation, adrenal chromaffin cells, 385
early production, 1,4,5-inositol trisphosphate, ileal smooth muscle, 513
- β -Carbolines, benzodiazepine-receptor ligands, stereochemical features, 334
- Carboxylesterases, hepatic microsomal, multiplicity and regulation (rat), 579
- Carcinogens, *N*-sulfonyl-2-acetylaminofluorene, solvolysis and metabolic degradation, liver (rat), 438
- Cardiac cells, beating rates, intracellular cAMP levels, *Bordetella adenylate cyclase* (chick), 529
- Cardiac sarcolemma, diltiazem receptors, binding site (dog), 175
- Cell cycle, effect of pseudopterosin A, DNA and protein synthesis, embryos (sea urchin), 500
- Central nervous system, GTP-binding protein, immunological localization, vertebrates and invertebrates, 313
- Cerebral cortex, α_1 -adrenergic receptors, phosphatidylinositol turnover, cyclic AMP accumulation (rat), 239
- CGS 9343B, potent and novel calmodulin inhibitor, 535
- Chromaffin cells, α -bungarotoxin site, up-regulation, nicotinic antagonists, 385
- Clonidine, α_2 -adrenergic turnover, adipose tissue and kidney, benextramine (hamster), 89
- Clotrimazole, induction, cytochrome P-450, 135
- c-myc*, differentiation, retinoic acid and calcium ionophore A23187, 140
- Computer models
radioligand binding, evaluation for analysis, 103
structure evaluation, antileukemic 9-anilinoacridines, 457
- Cyclic AMP
beating rates of cardiac cells, *Bordetella adenylate cyclase* (chick), 529
protein kinase, binding, *N*-[2-(methylamino)ethyl]-5-isoquinoline-sulfonamide, 523
- Cysteine, oxidation of thiol drugs, lactoperoxidase/hydrogen peroxide system, 417
- Cysteine conjugate
 β -lyase, α -ketoacids, *S*-(1,2-dichlorovinyl)-L-cysteine, 208
transport in LLC-PK₁ cells, role, toxicity, 506
- Cytochalasin B, glucose transport activity, forskolin inhibition, adipose cells (rat), 279
- Cytochrome P-450
altered regulation, choline-deficient cirrhotic liver (rat), 117
cDNA clone, characterization, compared with mRNA levels (rat), 152
clotrimazole induction, 135
genes, developmental regulation (rat), 477
hepatic metabolism, phenelzine, free radical pathways, 213
isozyme 5, species-dependent expression, liver and lung (rabbit, guinea pig, mouse, monkey, hamster, rat), 320
- Cytomegalovirus, replication, selective inhibition, 1-(2'-deoxy-2'-fluoro- β -D-arabinofuranosyl)-5-fluorouracil, 301
- Cytotoxicity
anthracycline amino group, function, cellular transport, 552
deoxyuridine metabolism, mercury toxicity, 200
S-(1,2-dichlorovinyl)L-cysteine, α -ketoacids, cysteine conjugate β -lyase, 208
- D**
- Daunomycin, function of anthracycline amino group, cellular transport, cytotoxicity, 552
- DDT₁ MF-2 cells, agonist-induced changes, β - and α_1 -adrenergic receptors, 58
- Debrisoquine, cytochrome P-450 cDNA clone, characterization, compared with mRNA levels (rat), 152
- 1-(2'-Deoxy-2'-fluoro- β -D-arabinofuranosyl)-5-fluorouracil, selective inhibition, human cytomegalovirus replication, 301
- Deoxyuridine, metabolism, mercury toxicity, 200
- Dexamethasone, glucocorticoid regulation, β -adrenergic receptors, 3T3-L1 preadipocytes, 377
- Dihydrofolate reductase, kinetic and molecular properties, pyrimethamine, *Plasmodium falciparum*, 430
- Dihydropyridines
binding, calcium channel function, adrenal medullary tumor cells (rat), 401
binding and electrophysiological effects, cardiac membranes (guinea pig), 221
- Diltiazem, binding site, other calcium entry blockers, cardiac sarcolemma (dog), 175
- 3,5-Dimethylacetaminophen, acetaminophen toxicity, mechanisms of, hepatocytes (rat), 647
- Diprenorphine, repeated electroconvulsive shock, effect, opioid-binding sites, 562
- DNA
cytochrome P-450, characterization, compared with mRNA levels (rat), 152
deoxyuridine metabolism, mercury toxicity, 200
effect of pseudopterosin A, cell division and cycle progression, embryos (sea urchin), 500
incorporation of (*E*)-5-(2-iodovinyl)-2'-deoxyuridine, varicella-zoster virus, 493
nuclear, doxorubicin binding, effect of microsomes (rat), 307
- DNA polymerase, inhibition, reaction, selenite with sulfhydryl compounds, 112
- DNA primase, inhibition, nucleoside triphosphates, 146
- Dopamine, receptors, *see* Receptors
- Doxorubicin
binding, effect of microsomes, hepatic nuclear DNA (rat), 307
function of anthracycline amino group, cellular transport, cytotoxicity, 552
- Drug delivery, incorporation into liposomes, amphotericin B, selective toxicity, 1

E

- Embryos, effect of pseudopterosin A, cell division and cycle progression, DNA (sea urchin), 500
- EMD 23,448, receptor occupancy and response, striatal dopamine autoreceptors (rat), 592
- Enantiomers, binding and electrophysiological effects, dihydropyridines, cardiac membranes (guinea pig), 221
- Enkephalin analogs, δ opioid receptor binding, structural requirements, 599
- Epithelial cells, muscle and kidney, α_1 -adrenergic receptor, guanine nucleotide-binding protein, 12
- Erythrocytes, blood binding, anthranilic acid derivatives, 294
- Ethanol, diminished pentose cycle flux, perfused liver (rat), 631
- N*-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, receptor occupancy and response, striatal dopamine autoreceptors (rat), 592

F

- Fetus, cytochrome P-450 genes, developmental regulation (rat), 477
- Fibroblasts, 3T3-L1 preadipocytes, glucocorticoid regulation, β -adrenergic receptors, 377
- Floctafenac acid, blood binding, anthranilic acid derivatives, 294
- Fluorescence, bisquaternary phenanthridinium, site selectivity, acetylcholinesterase, 610
- Folic acid, role of, folate-dependent enzymes, methanol poisoning, 557
- Polypolyglutamate synthetase, inhibition, liver, non- γ -glutamylatable antifolate analogs, 122
- Formate, role of folic acid, human methanol poisoning, 557
- Forskolin
 - D_1 dopamine receptor, modification, *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (rat), 50
 - glucose transport, adipose cells, interaction with glucose transporter (rat), 279
- Fourier transform, infrared studies, phospholipid hydration, volatile anesthetics, 623
- Free radicals
 - oxygen-dependent effect of microsomes, doxorubicin binding, hepatic nuclear DNA (rat), 307
 - pathways, hepatic metabolism, phenelzine, 213

G

- Glafenic acid, high affinity binding, blood binding, anthranilic acid derivatives, 294
- Glucose, transport activity, forskolin inhibition, adipose cells (rat), 279
- Glucocorticoids, regulation of β -adrenergic receptors, 3T3-L1 preadipocytes, 377
- Glucuronidation
 - phenol, induction deficiency, 3-methylcholanthrene (rat), 585
 - UDP-glucuronosyltransferases, isolation and purification, human liver, 27
- Glutathione
 - acetaminophen toxicity, mechanisms of, hepatocytes (rat), 647
 - biliary secretion, stimulation of, sulfonylureas (rat), 638
 - oxidation of thiol drugs, lactoperoxidase/hydrogen peroxide system, 417
- Glutathione *S*-transferases, nitrogen mustard-resistant and -sensitive cell lines, 575
- Glyburide, biliary glutathione secretion, stimulation of, sulfonylureas (rat), 638
- Gold compounds, auranofin, resistance, induction of metallothionein, 21
- GTP-binding proteins, immunological localization, different tissues, vertebrates and invertebrates, 313
- Guanine nucleotide binding protein
 - phorbol ester-mediated inhibition, vasopressin, β -adrenergic responses (rat), 180
 - radioligand binding, evaluation of models, analysis, 103

- Guanine nucleotide regulatory protein, α_1 -adrenergic receptor, epithelial cells, muscle and kidney, 12
- Guanosine nucleotides, calcium and, β -melanotropin receptor function, M2R melanoma cell line, 81
- Guanosine triphosphatase, adenylate cyclase and, desensitization, NG108-15 cells, 159
- Guanyl nucleotide, 4-bromo-2,5-dimethoxyphenylisopropylamine label, cortical serotonin receptors, 194

H

- Hepatocytes
 - acetaminophen toxicity, mechanisms of (rat), 647
 - role of histamine receptors, effects, metabolism (rat), 253
- Herpes simplex virus, *E*-5-(2-bromovinyl)-2'-deoxyuridine, 1 β -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, comparative metabolism, 422
- Hippocampus
 - α_1 -adrenergic receptors, phosphatidylinositol turnover, cyclic AMP accumulation (rat), 239
 - serotonin receptors, coupled to adenylate cyclase, characterization (guinea pig), 357
- Histamine
 - early production, 1,4,5-inositol trisphosphate, ileal smooth muscle, 513
 - effects on metabolism, receptors, hepatocytes (rat), 253
 - H_2 -receptors, triazole and tetrazole, molecular determinants, 345
 - H_2 -receptor antagonists, structure-activity relationship, NMR spectra, 410
- HL-60 cells, differentiation, retinoic acid and calcium ionophore A23187, 140
- Hydrogen peroxide, lactoperoxidase and, oxidation of thiol drugs, 417
- 3-(3-Hydroxyphenyl)-*N*-*n*-propylpiperidine, receptor occupancy and response, striatal dopamine autoreceptors (rat), 592
- 5-Hydroxytryptamine, *see* Serotonin

I

- Ileum, selectivity of partial agonists, oxotremorine, muscarinic receptor reserve (guinea pig), 351
- Imidazoles, *N*-substituted, cytochrome P-450, 135
- Inositol lipids, hydrolysis, leukotriene D_4 receptor (guinea pig), 35
- Inositol phosphates
 - phorbol ester-mediated inhibition, vasopressin, β -adrenergic responses (rat), 180
 - phosphatidylinositol turnover, cyclic AMP accumulation, α_1 -adrenergic receptors (rat), 239
- 1,4,5-Inositol trisphosphate, 1,3,4,5-inositol tetrakisphosphate and, early production, ileal smooth muscle, 513
- (*E*)-5-(2-Iodovinyl)-2'-deoxyuridine, incorporation into deoxyribonucleic acids, varicella-zoster virus, 493
- Isoproterenol, β -adrenergic receptor, coupled to adenylate cyclase, redox mechanism (frog), 368
- Isozymes
 - hepatic microsomal carboxylesterases, multiplicity and regulation (rat), 579
 - UDP-glucuronosyltransferase, induction deficiency, phenol glucuronidation (rat), 585

K

- α -Ketoacids, cysteine conjugate β -lyase, cytotoxicity, *S*-(1,2-dichlorovinyl)-L-cysteine, 208
- Kidney
 - α_2 -adrenergic turnover, adipose tissue, benextramine (hamster), 89
 - epithelial cells, α_1 -adrenergic receptor, guanine nucleotide-binding protein, 12
 - microsomal flavin-containing monooxygenase, tissue- and species-dependent expression (rabbit, rat, guinea pig, hamster, mouse, pig), 569
 - radiolabeled vasopressin antagonist, SK&F 101926, 267

L

- Lactoperoxidase, hydrogen peroxidase system, oxidation of thiol drugs, 417
- L929 cells, vaccinia virus multiplication, adenosine dialdehyde (mouse), 485
- Leukemia, antileukemic 9-anilinoacridines, computer-automated structure evaluation, 457
- Levamisole, cholinergic receptor, *Caenorhabditis elegans*, 185
- Ligands
 benzodiazepine-receptor, stereochemical features, binding, 334
 dissociation constants, competition binding assays, 603
 fluorescent bisquaternary phenanthridinium; site selectivity, acetylcholinesterase, 610
 morphine receptor-specific, characterization of binding (rat), 326
 specificity, microsomal antiestrogen-binding sites, 541
- Lipids
 amphotericin B, selective toxicity, liposomes, 1
 membrane perturbation, effect, β -adrenoceptor blocking drugs, 97
- Lipolysis, α_2 -adrenergic turnover, adipose tissue and kidney, benextramine (hamster), 89
- Lipoproteins, blood binding, anthranilic acid derivatives, 294
- Liposomes, incorporation of amphotericin B, selective toxicity, mechanism, 1
- Liver
 biliary glutathione secretion, stimulation of, sulfonylureas (rat), 638
 cirrhosis, choline deficiency, altered cytochrome P-450 (rat), 117
 cytochrome P-450
 genes, developmental regulation (rat), 477
 isozyme 5, species-dependent expression (rabbit, guinea pig, mouse, monkey, hamster, rat), 320
 folic acid, folate-dependent enzymes, methanol poisoning, 557
 solvolysis and metabolic degradation, *N*-sulfonyl-2-acetylaminofluorene (rat), 438
 UDP-glucuronosyltransferases, isolation, purification, 27
- LLC-PK₁ cells, transport of *S*-cysteine conjugates, role in toxicity, 506
- Lung
 cytochrome P-450, isozyme 5, species-dependent expression (rabbit, guinea pig, mouse, hamster, rat), 320
 microsomal flavin-containing monooxygenase, tissue- and species-dependent expression (rabbit, rat, guinea pig, hamster, mouse, pig), 569

M

- Magnesium, ryanodine binding, calcium-activated, mechanisms of modulation (rabbit), 232
- Mecamylamine, levamisole receptor, *Caenorhabditis elegans*, 185
- Melanoma cell line, M2R, β -melanotropin receptor function, adenylate cyclase, 81
- β -Melanotropin, receptor function, adenylate cyclase, calcium and guanosine nucleotides, 81
- Mercury, toxicity, deoxyuridine metabolism, 200
- Metallothionein, induction, resistance to auranofin, Chinese hamster ovary cells, 21
- Methanol, poisoning, role of folic acid, 557
- N*-[2-(Methylamino)ethyl]-5-isoquinolinesulfonamide, specific binding to active site, cAMP-dependent protein kinase, 523
- 3-Methylcholanthrene, induction deficiency, phenol glucuronidation (rat), 585

- Methylenes, binding site (82-93) of calmodulin, trifluoperazine derivatives, 617
- Microsomes
 flavin-containing monooxygenase, tissue- and species-dependent expression (rabbit, rat, guinea pig, hamster, mouse, pig), 569
 multiplicity and regulation of carboxylesterases (rat), 579
 oxygen-dependent effect, doxorubicin binding, hepatic nuclear DNA (rat), 307
- Mitochondria, selenite-induced NADPH oxidation, calcium release (guinea pig), 643
- Molecular electrostatic potentials, triazole and tetrazole analogs, histamine H₂-receptors, 345
- Monooxygenase, flavin-containing, mammalian microsomal, tissue- and species-dependent expression (rabbit, rat, guinea pig, hamster, mouse, pig), 569
- Muscle, bovine trapezius, shallow agonist competition, *beta* adrenoceptors, 69
- Muscle, skeletal, ryanodine binding, calcium-activated, mechanisms of modulation (rabbit), 232
- Muscle, smooth
 DDT₁ MF-2 cells, agonist-induced changes, adrenergic receptors, 58
 epithelial cells, α_1 -adrenergic receptor, guanine nucleotide-binding protein, 12
 ileal, early production, 1,4,5-inositol trisphosphate, 513
 phorbol ester inhibition, β -adrenergic responses (rat), 180
 radiolabeled vasopressin antagonist, SK&F 101926, 267
 vascular vasopressin receptors, identification, characterization (rat), 259

N

- NADPH
 pentose cycle flux, perfused liver, ethanol-fed rat, 631
 selenite-induced oxidation, calcium release, mitochondria (guinea pig), 643
- N*-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, modification, D₁ dopamine receptor (rat), 50
- Neurotoxins, binding to sodium channels, allosteric modulation, 273
- NG108-15 cells, desensitization, GTPase, adenylate cyclase, 159
- Nicotine
 acetylcholine and, same recognition site, brain (rat), 169
 kinetics and mechanism of binding, high affinity receptor sites, brain (rat), 392
- Nicotinic antagonists, α -bungarotoxin site, up-regulation, adrenal chromaffin cells, 385
- Nitrendipine, dihydropyridine binding, calcium channel function, adrenal medullary tumor cells (rat), 401
- Nitrogen mustard, -resistant and -sensitive cell lines, glutathione *S*-transferases, 575
- Norepinephrine, phosphatidylinositol turnover, cyclic AMP accumulation in brain, α_1 -adrenergic receptors (rat), 239
- Nuclear magnetic resonance, structure-activity relationship, histamine H₂-receptor antagonists, 410
- Nucleoside analogues, *E*-5-(2-bromovinyl)-2'-deoxyuridine, 1- β -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil and, comparative metabolism, 422
- Nucleoside triphosphates, inhibition, DNA primase, 146

O

- Olfactory bulb, repeated electroconvulsive shock, effect, opioid-binding sites, 562
- Opioids, binding sites, effect, repeated electroconvulsive shock, 562
- Ovary cells, Chinese hamster, induction of metallothionein, resistance, auranofin, 21
- Oxotremorine, selectivity of partial agonists, muscarinic receptor reserve, ileum and urinary bladder (guinea pig), 351

P

- Penicillamine, oxidation of thiol drugs, lactoperoxidase/hydrogen peroxide system, 417
- Pentose, cycle flux, perfused liver, ethanol-fed rat, 631
- Pertussis toxin
 α_1 -adrenergic receptor, guanine nucleotide-binding protein, epithelial cells, 12
 GTP-binding protein, immunological localization, vertebrates and invertebrates, 313
- Phenanthridinium ligands, fluorescent bisquaternary, site selectivity, acetylcholinesterase, 610
- Phenelzine, hepatic metabolism, free radical pathways, 213
- Phenol, glucuronidation, induction deficiency, 3-methylcholanthrene (rat), 585
- Phenothiazines, binding site (82-93) of calmodulin, trifluoperazine derivatives, 617
- Phorbol esters, inhibition, vasopressin, β -adrenergic responses (rat), 180
- Phosphatidylinositol
 α_1 -adrenergic receptor, guanine nucleotide-binding protein, epithelial cells, 12
 turnover, cyclic AMP accumulation, α_1 -adrenergic receptors (rat), 239
- Phosphodiesterases, adenosine receptor antagonists, selectivity, A_1 receptor subtype, 247
- Phospholipase C, leukotriene D_4 receptor, hydrolysis, inositol lipids in lung (guinea pig), 35
- Phospholipids, hydration, Fourier transform infrared studies, volatile anesthetics, 623
- Photoaffinity labeling
 benzodiazepine-binding sites, peripheral-type, 42
 D_1 dopamine receptors, identification, binding subunit (rat), 129
- PK 14105, benzodiazepine-binding sites, peripheral-type, photoaffinity labeling, 42
- PL17, characterization of binding (rat), 326
- Plasmodium reductase*, pyrimethamine-sensitive and -resistant clones, dihydrofolate reductase, kinetic and molecular properties, 430
- Polyglutamylation, non- γ -glutamylatable antifolate analogs, inhibition, folypolyglutamate synthetase, 122
- Propidium, fluorescent bisquaternary phenanthridinium, site selectivity, acetylcholinesterase, 610
- Protein
 binding, blood, anthranilic acid derivatives, 294
 synthesis, effect of pseudopterosin A, embryos (sea urchin), 500
- Protein kinase
 cAMP-dependent, specific binding, *N*-[2-(Methylamino)ethyl]-5-isoquinolinesulfonamide, 523
 differentiation, retinoic acid and calcium ionophore A23187, 140
- Protein kinase C, calmodulin inhibitor, CGS 9343B, 535
- Pseudopterosin A, cell division and cell cycle progression, DNA and protein synthesis, embryos (sea urchin), 500
- Ptychodiscus brevis*, neurotoxin binding, sodium channels, allosteric modulation, 273
- Pyrimethamine, sensitive and resistant clones, *Plasmodium falciparum*, dihydrofolate reductase, 430

R

- Radioligands
 binding assays, evaluation of models, analysis, 103
 ligand dissociation constants, competition binding assays, 603
- Receptors
 acetylcholine, levamisole receptor, *Caenorhabditis elegans*, 185
 adenosine, selectivity, A_1 receptor subtype, 247
 α -adrenergic, *see* Adrenoceptors
 β -adrenergic, *see* Adrenoceptors
 calcium-ryanodine, mechanisms of modulation (rabbit), 232
 D_1 dopamine

- binding subunit, photoaffinity crosslinking (rat), 129
 modification, *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (rat), 50
- dopamine autoreceptors, occupancy and response (rat), 592
- high affinity, brain, nicotine binding (rat), 392
- histamine, effects on metabolism, hepatocytes (rat), 253
- histamine H_2
 antagonists, structure-activity relationship, 410
 triazole and tetrazole, molecular determinants, 345
- leukotriene D_4 , hydrolysis, inositol lipids in lung (guinea pig), 35
- levamisole, *Caenorhabditis elegans*, 185
- morphine, ligand binding, PL17 (rat), 326
- muscarinic
 microsomal antiestrogen-binding sites, 541
 selectivity of partial agonists, oxotremorine (guinea pig), 351
- opiate, ligand binding, PL17 (rat), 326
- opioid
 desensitization, NG108-15 cells, 159
 effect, repeated electroconvulsive shock, 562
- δ opioid, binding, structural requirements, 599
- radioligand binding data, evaluation of models, analysis, 103
- serotonin
 4-bromo-2,5-dimethoxyphenylisopropylamine label, guanyl nucleotide, 194
 coupled to adenylate cyclase, characterization (guinea pig), 357
 vasopressin, identification and characterization, smooth muscle (rat), 259
- Retinoic acid, calcium ionophore A23187 and, differentiation, HL-60 cells, 140
- RNA, messenger
 adenosine dialdehyde, L929 cells (mouse), 485
 cytochrome P-450
 cDNA clone, characterization (rat), 152
 genes, developmental regulation (rat), 477
- RNA polymerase, inhibition, reaction, selenite with sulfhydryl compounds, 112
- Ryanodine, binding, calcium-activated, mechanisms of modulation (rabbit), 232

S

- Salicylic acid, anti-inflammatory action, electronic determinants (mouse), 284
- Sarcoplasmic reticulum, ryanodine binding, calcium-activated, mechanisms of modulation (rabbit), 232
- SCH23390, D_1 dopamine receptor, modification, *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (rat), 50
- Selenite
 induced NADPH oxidation, calcium release, mitochondria (guinea pig), 643
 reaction with sulfhydryl compounds, inhibition, RNA and DNA polymerases, 112
- Serotonin
 coupled to adenylate cyclase, characterization, hippocampal membranes (guinea pig), 357
 receptors, 4-bromo-2,5-dimethoxyphenylisopropylamine label, guanyl nucleotide, 194
- Sex differences, cytochrome P-450 cDNA clone, characterization, compared to mRNA levels (rat), 152
- Shock, repeated electroconvulsive, effect, opioid-binding sites, 562
- SKF 102922, leukotriene D_4 receptor, hydrolysis, inositol lipids in lung (guinea pig), 35
- Sodium, repeated electroconvulsive shock, effect, opioid-binding sites, 562
- Sodium channels, voltage-sensitive, neurotoxin binding, allosteric modulation, 273
- Sparteine, cytochrome P-450 cDNA clone, characterization, compared with mRNA levels (rat), 152

Spectroscopy

- electron spin resonance, effect, β -adrenoceptor blocking drugs, 97
- Fourier transform infrared, phospholipid hydration, volatile anesthetics, 623

Spiperone, serotonin receptors, coupled to adenylate cyclase, characterization (guinea pig), 357

Stereochemistry, benzodiazepine-receptor ligands, 334

Steroids, impaired hydroxylation, choline-deficient cirrhotic liver, cytochrome P-450 (rat), 117

Striatum, D₁ dopamine receptors, identification, binding subunit (rat), 129

Sulfhydryl compounds, reaction with selenite, inhibition, RNA and DNA polymerases, 112

N-Sulfonyl-2-acetylaminofluorene, solvolysis and metabolic degradation, liver (rat), 438

Sulfonylureas, biliary glutathione secretion, stimulation of (rat), 638

T

Tetrazole analogs, triazole and, molecular determinants, histamine H₂-receptors, 345

Thiols, oxidation, lactoperoxidase/hydrogen peroxide system, 417

Tolbutamide, biliary glutathione secretion, stimulation of, sulfonylureas (rat), 638

Toxicity, role, *S*-cysteine conjugates, transport in LLC-PK₁ cells, 506

Triazole, tetrazole analogs and, molecular determinants, histamine H₂-receptors, 345

Trifluoperazine

- calmodulin inhibitor, CGS 9343B, 535

- differentiation, retinoic acid and calcium ionophore A23187, HL-60 cells, 140

Trifluoperazine derivatives, binding to site (82-93) of calmodulin, 617

Tumor cells, adrenal medulla, dihydropyridine binding, calcium channel function (rat), 401

Tyrosine kinase, differentiation, retinoic acid and calcium ionophore A23187, HL-60 cells, 140

Tyr-Pro-NMePhe-D-Pro-NH₂, *see* PL17

U

UDP-glucuronosyltransferase

- clotrimazole induction, cytochrome P-450, 135

- defective induction, phenol glucuronidation, 3-methylcholanthrene (rat), 585

- human liver, isolation, purification, 27

Uracil-DNA glycosylase, deoxyuridine metabolism, mercury toxicity, 200

Ureagenesis, role of histamine receptors, effects on metabolism, hepatocytes (rat), 253

Urinary bladder, selectivity of partial agonists, oxotremorine, muscarinic receptor reserve (guinea pig), 351

V

Vaccinia virus, adenosine dialdehyde, inhibitor of multiplication, L929 cells (mouse), 485

Varicella-zoster virus, incorporation, (*E*)-5-(2-iodovinyl)-2'-deoxyuridine, DNA, 493

Vasopressin

- novel radiolabeled antagonist, SK&F 101926, 267

- phorbol ester inhibition, β -adrenergic responses (rat), 180

- receptors, identification and characterization, smooth muscle (rat), 259

- vascular, receptors, smooth muscle (rat), 259

Veratridine, α -bungarotoxin site, up-regulation, adrenal chromaffin cells, 385

W

Walker 256 carcinoma, nitrogen mustard-resistant and -sensitive cell lines, glutathione *S*-transferases, 575

X

Xanthines, adenosine receptor antagonists, selectivity, A₁ receptor subtype, 247

Y

Yohimbine, α_2 -adrenergic turnover, adipose tissue and kidney, benextramine (hamster), 89

Leading Pharmacology Journals

Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Editor: **Eva King Killam, PhD**

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology. **Monthly**

DRUG METABOLISM AND DISPOSITION

The Biological Fate of Chemicals

Editor: **Vincent G. Zannoni, PhD**

DRUG METABOLISM AND DISPOSITION publishes *in vitro* and *in vivo* experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preservatives. The areas covered are • pharmacokinetics, pharmacodynamics, and mechanisms • genetic, nutritional, or hormonal factors affecting the biological fate of chemicals • toxicological consequences of xenobiotic metabolism. **Bimonthly**

PHARMACOLOGICAL REVIEWS

Editor: **James A. Bain, PhD**

PHARMACOLOGICAL REVIEWS is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. **Quarterly**

MOLECULAR PHARMACOLOGY

Editor: **William A. Catterall, PhD**

The papers published in **MOLECULAR PHARMACOLOGY** are on the cutting edge of research on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology are juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including such areas as molecular mechanisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. **Monthly**




Order free by phone. Call 1-800-638-6423 from anywhere in the U.S. except AK and HI. MD residents, call 528-4105 collect.



Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203
266 Fulham Road
London SW10 9EL England



YES! Enter my subscriptions to the following:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscriptions today!

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (monthly)

Individual: \$140/yr Institutions: \$220/yr
(Please add \$30.00 outside the U.S.)

New Subscription Renewal 3 yrs 2 yrs 1 yr

DRUG METABOLISM AND DISPOSITION (bimonthly)

Individual: \$60/yr Institutions: \$95/yr
(Please add \$10.00 outside the U.S.)

New Subscription Renewal 3 yrs 2 yrs 1 yr

MOLECULAR PHARMACOLOGY (monthly)

Individual: \$75/yr Institutions: \$165/yr
(Please add \$15.00 outside the U.S.)

New Subscription Renewal 3 yrs 2 yrs 1 yr

PHARMACOLOGICAL REVIEWS (quarterly)

Individual: \$35/yr Institutions: \$70/yr In-training: \$25/yr
(Please add \$10.00 outside the U.S.)

New Subscription Renewal 3 yrs 2 yrs 1 yr

Payment options:

Check enclosed Bill me
 VISA MasterCard American Express

card # _____

signature/P.O.# _____

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. Rates valid for orders received before October 31, 1987.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request. Residents, fellows, interns, and students when requesting the in-training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

name _____

address _____

city state zip _____

Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203

266 Fulham Road
London SW10 9EL, England

ASPETAD 93180 87



Broad coverage of pharmacology
in a prestigious journal

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS


Editor: **Eva King Killam, PhD**, School of Medicine, University of California, Davis

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including:

- autonomic pharmacology
- analgesia
- behavioral pharmacology
- cardiovascular pharmacology
- cellular pharmacology
- chemotherapy
- clinical pharmacology
- developmental pharmacology
- drug abuse
- drug metabolism & disposition
- gastrointestinal pharmacology
- immunopharmacology
- neuropharmacology
- pulmonary pharmacology
- renal pharmacology
- toxicology

JPET is valuable reading for academic, industrial and clinical pharmacologists as well as toxicologists. The Journal deserves a place in every pharmaceutical and toxicological research laboratory and pharmacology/toxicology department throughout the world.

Monthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

The Journal of Pharmacology and Experimental Therapeutics (monthly)

- Individual: \$140/yr Institutions: \$220/yr
(Please add \$30.00 outside the U.S.)
 New Subscription Renewal 3 yrs 2 yrs 1 yr

name _____

address _____

city state zip _____

Payment options:

- Check enclosed Bill me
 VISA MasterCard American Express

card # _____

signature/P.O.# _____

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, in US dollars only. Rates valid for orders received before October 31, 1987.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request. *Residents, fellows, interns, and students*, when requesting the in-training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

Williams & Wilkins

P.O. Box 23291
Baltimore, Maryland 21203

266 Fulham Road
London SW10 9EL, England

PTAD 93775 87



INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. William A. Catterall, Editor, *Molecular Pharmacology*, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Bauge, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (×, ○, ●, □, ■, △, ▲, ⊙). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.